Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
News|Podcasts|October 14, 2026
ACT Brief: Design Drivers of Trial Representation, eSource-to-EDC Data Automation, and Roche's ALK7 Obesity License
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
her October column , Rebecca Johnson, PhD, argues that representation gaps are built into protocol design, eligibility criteria, and site placement decisions long before recruitment begins. Only 24% of sponsors systematically benchmark disease demographics against enrolled populations, and sites remain clustered in urban areas while patients routinely travel more than 50 miles to participate. Johnson proposes an inclusion-by-design framework that treats representation as a foundational input rather than an operational overlay. IgniteData and RealTime eClinical Solutions announced a partnership enabling sites to transfer clinical data directly from eSource platforms to sponsor electronic data capture systems, eliminating manual transcription between systems. RealTime serves more than 3,000 research sites across 30 countries, while Archer is deployed at 80% of the National Cancer Institute's Designated Cancer Centers. The integration reduces coordinator burden and allows sponsors to accelerate data acquisition timelines.Roche licensed an RNAi candidate targeting ALK7 from Rona Therapeutics for obesity under a deal worth up to $100 million upfront and up to 1.06 billion dollars in additional milestone payments. ALK7, expressed in adipose tissue, reduces visceral and ectopic fat while preserving lean mass through direct tissue targeting rather than appetite suppression. The mechanism positions it as potentially complementary to existing GLP-1 therapies.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
Trending on Applied Clinical Trials Online
1
IgniteData and RealTime Partner to Streamline Clinical Data Transfer From eSource to Sponsor Systems
2
The Biggest Remaining Barriers to High-Quality RWE Across Oncology Data Platforms
3
Beyond Outreach: Structural Drivers of Representation in Clinical Trials
4
Flexible Clinical Operations and Site Management Across a Diversified Biotech Portfolio: An Application of Quality by Design and Risk-Based Oversight
5